|
|
|
|
|
Acyclovir
drug data and news
Acyclovir drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Acyclovir | ||
| Brand Names/Synonyms | AC2; Aciclovier; Aciclovir; Acycloguanosine; Acyclovir; Acyclovir Sodium; Alti-Acyclovir; Avirax; BW-248U; Valtrex; Vipral; Virorax; Wellcome-248u; Zovirax; Zovirax Wellstat Pac; Zovirax Zostab Pac | ||
| Indication | For the treatment and management of herpes zoster (shingles), genital herpes, and chickenpox | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Acyclovir is a synthetic deoxyguanosine analog and it is the prototype antiviral agent that is activated by viral thymidine kinase. The selective activity of acyclovir is due to its affinity for the thymidine kinase enzyme encoded by HSV and VZV. | ||
| Mechanism Of Action | Viral (HSV-1, HSV-2 and VZV) thymidine kinase converts acyclovir to the acyclovir monophosphate, which is then converted to the diphosphate by cellular guanylate kinase, and finally to the triphosphate by phosphoglycerate kinase, phosphoenolpyruvate carboxykinase, and pyruvate kinase. Acyclovir triphosphate competitively inhibits viral DNA polymerase and competes with the natural deoxyguanosine triphosphate, for incorporation into viral DNA. Once incorporated, acyclovir triphosphate inhibits DNA synthesis by acting as a chain terminator. | ||
| Acyclovir News (When available) |
Deconstructing Myogen's market cap 07 Mar 2006 Pfizer launches Revatio in UK for lung disease 07 Mar 2006 Actelion dips as Glaxo bolsters rival drug 07 Mar 2006 FDA MedWatch - Tracleer (Bosentan): Recommended Dosage Adjustment ... Mar 2, 2006 Actelion 2005 profit rises 44 pct, Tracleer shines Feb 22, 2006 UPDATE 2-Actelion 2005 profit rises 44 pct, Tracleer shines Feb 22, 2006 FDA and Actelion Pharmaceuticals Issue ‘Reminder’ of ... Mar 3, 2006 UPDATE 1-New liver damage info added to Actelion drug label Mar 2, 2006 Actelion "Dear Doctor" Letter No Problem -GS Mar 3, 2006 (PZ) Actelion Announces Full Year 2005 Financial Results Feb 22, 2006 Swiss pharma Actelion's profit rises 5%, sales gain 44% Feb 23, 2006 JP Morgan Starts Actelion At Overweight Feb 28, 2006 Actelion Rebounds From Thu 'Over-Reaction' Mar 3, 2006 UPDATE 3-Actelion 05 profit rises, outlook disappoints Feb 23, 2006 European Technology Stocks Fall; ASML Slides, Vodafone Advances Mar 3, 2006 European Stocks Climb; Adecco, BP, Publicis Shares Pace Gains Mar 3, 2006 Actelion FY sales beat consensus but earnings miss Feb 22, 2006 Credit Suisse Cuts Actelion Target To CHF140 Feb 24, 2006 WestLB Lifts Actelion's Target Feb 24, 2006 Lehman Lifts Actelion Target To CHF142 Feb 24, 2006 Actelion Top-Line Growth Surprises Feb 23, 2006 Actelion Shr Price Reaction Overdone -ZKB Mar 2, 2006 WestLB Cuts Actelion To Hold Vs Buy >ATLN.EB Feb 23, 2006 Stakeholder Perspectives: Pulmonary Arterial Hypertension - A ... Jan 31, 2006 Stakeholder Perspectives: Pulmonary Arterial Hypertension - A ... Jan 31, 2006 Bear Stearns Resumes Actelion At Peer Perform Jan 27, 2006 Roche, Actelion To Benefit From Lupus Jan 12, 2006 | ||
| Dosage Forms | Intravenous Infusion; Capsules; Tablets; Suspension; Topical Cream; Topical Ointment | ||
| Drug_Category | Antivirals; Nucleosides and Nucleotides (08:18.32); ATC:J05AB | ||
| Absorption | Oral _ Bioavailability 10 to 20% | ||
| Interactions | Co-administration of probenecid with acyclovir has been shown to increase the mean half-life and the area under the concentration-time curve. Urinary excretion and renal clearance were correspondingly reduced. The clinical effects of this combination have not been studied. | ||
| Toxicity | Acyclovir may cause nephrotoxicity (crystallization of acyclovir within renal tubules, elevation of serum creatinine, transient), and neurotoxicity (coma, hallucinations, lethargy, seizures, tremors). Nephrotoxicity and neurotoxicity usually resolve after cessation of acyclovir therapy. However, there is no well-defined relationship between acyclovir concentrations in the blood and these adverse effects. | ||
| Organisms Affected | Not Available | ||
| Chemical IUPAC Name | 2-amino-9-(2-hydroxyethoxymethyl)-3H-purin-6-one | ||
| Chemical Formula | C8H11N5O3 | ||
| Molecular Weight | 225.205 g/mol | ||
| Smiles String | C1=NC2=C(N1COCCO)NC(=NC2=O)N | ||
| Melting Point | 256.5 - 257 °C | ||
| Water Solubility | 3.399 mg/L | ||
| State | white to almost white crystalline powder | ||
| LogP/Hphobicity | -1.314 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic; the only major urinary metabolite that has been detected is 9_carboxymethoxymethylguanine | ||
| Half Life | 2.5-3.3 hours | ||
| Protein Binding [%] | 9%-33% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Acyclovir.html http://www.rxlist.com/cgi/generic/acyclo.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00567 | ||
| CAS Registry Number | 59277-89-3 | ||
| KEGG Compound ID | C06810 | ||
| PubChem ID | SID:63115 | ||
| PharmGKB ID | PA448045 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2242784 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |